Previous 10 | Next 10 |
home / stock / aavxf / aavxf news
PARIS, FRANCE / ACCESSWIRE / October 16, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in pati...
Oral presentation of Phase 2b, 96-week, open-label, maintenance efficacy and safety in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC) Moderated poster presentation highlighting correlation of pharmacokinetic (PK) parameters with enhanced expression of ...
PARIS, FRANCE / ACCESSWIRE / August 23, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company") today announced the appointment of Patrick Malloy as new Senior Vice President Investor Relations. Mr. Malloy brings 20 years of investor relations and commercial leadership...
Up to EUR 75M from Kreos Capital and Claret European Growth Capital Up to EUR 75M from Heights Capital Management EUR 27M of additional cash resources for Abivax at drawdown of the first tranches PARIS, FRANCE / ACCESSWIRE / August 21, 2023 / Abivax SA (Euronext Paris : FR001233328...
PARIS, FRANCE / ACCESSWIRE / August 10, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares, in the United States, subject to market and other conditions, an...
PARIS, FRANCE / ACCESSWIRE / July 11, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces today the appointment of...
The award recognizes a significant capital market transaction in the biotech sector Abivax received the award for its oversubscribed EUR 130M cross-over financing at market price with top-tier US and European Biotech investors in February 2023 PARIS, FRANCE / ACCESSWIRE / June 15, 2023 ...
As of June 1st, the Abivax stock is represented in the MSCI Indexes The MSCI Indexes reflect the evolution of the world's equity markets to support investors building effective portfolios based on risk and return assessments PARIS, FRANCE / ACCESSWIRE / June 8, 2023 / Abivax (Euronext ...
Shareholders approved all proposed resolutions PARIS, FRANCE / ACCESSWIRE / June 8, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflamm...
As Chief People Officer of Abivax, Ida Hatoum will be leading the organizational strategy to build and strengthen the Abivax team in the United States and Europe across all functions Ida has a proven track record in talent acquisition and development in the biopharmaceutical industry PAR...
News, Short Squeeze, Breakout and More Instantly...
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with ...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabi...
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...